Inhibitor of DNA-binding (Id) proteins prevent cell differentiation, promote growth and sustain tumour development. They do so by binding to E proteins and other transcription factors through the helix-loop-helix (HLH) domain, and inhibiting transcription. This makes HLH-mediated Id protein interactions an appealing therapeutic target. We have used the dominant interfering HLH dimerization mutant 13I to model the impact of Id inhibition in two human neuroblastoma cell lines: LA-N-5, similar to immature neuroblasts, and SH-EP, resembling more immature precursor cells. We have validated 13I as an Id inhibitor by showing that it selectively binds to Ids, impairs complex formation with RB, and relieves repression of E protein-activated transcription. Id inactivation by 13I enhances LA-N-5 neural features and causes SH-EP cells to acquire neuronal morphology, express neuronal proteins such as N-CAM and NF-160, proliferate more slowly, and become responsive to retinoic acid. Concomitantly, 13I augments the cell-cycle inhibitor p27 Kip1 and reduces the angiogenic factor vascular endothelial growth factor. These effects are Id specific, being counteracted by Id overexpression. Furthermore, 13I strongly impairs tumorigenic properties in agar colony formation and cell invasion assays. Targeting Id dimerization may therefore be effective for triggering differentiation and restraining neuroblastoma cell tumorigenicity.
Introduction
Inhibitor of DNA-binding (Id) proteins are helix-loophelix (HLH) transcription factors playing a crucial role in developmental processes (Ruzinova and Benezra, 2003) . They maintain self-renewal, pluripotency and an undifferentiated state of progenitor cells, whereas their expression is extinguished on cell cycle exit and differentiation (Ying et al., 2003; Bai et al., 2007; Jankovic et al., 2007) . Ids (ID1-4) have highly homologous HLH domains but are devoid of a DNA-binding region. They primarily work as dominant negative regulators of bHLH transcription factors, crucial to trigger cell cycle arrest and differentiation. Through the HLH domain, Ids associate with the ubiquitous bHLHs, the E proteins, preventing DNA binding and complex formation with tissue-specific bHLHs (Ruzinova and Benezra, 2003) . They also interact with non-bHLH proteins such as PAX, ETS, ELK and underphosphorylated RB (Iavarone et al., 1994; Ohtani et al., 2001; Roberts et al., 2001; Chassot et al., 2007) .
Although their precise function is still debated, large volumes of evidence suggest that Ids have a role in cancer. They promote tumorigenesis in mice, directly interact with proteins implicated in cancer such as RB and ETS, are upregulated by MYC and RAS oncoproteins, and have a role in sustaining tumour angiogenesis in vivo (Lyden et al., 1999; Lasorella et al., 2005; Perk et al., 2005) . Although absent, or barely present, in most normal tissues, Ids are frequently upregulated in human cancer, their presence correlating to proliferation, invasiveness and neoangiogenesis (Perk et al., 2005; Iavarone and Lasorella, 2006) . Therefore, Ids are considered as potentially versatile therapeutic targets. Accordingly, a peptide-conjugated Id1 antisense oligonucleotide homed to tumour endothelium inhibited tumour growth and metastasis in two different murine models (Henke et al., 2008) .
The impact of Id inhibition in human cancer cells lines is not fully assessed. Ids are implicated in tumours originating from neural precursor cells, such as astrocytoma (Vandeputte et al., 2002) and neuroblastoma (Lasorella et al., 2000) , a neuroendocrine tumour arising from precursor cells of the peripheral nervous system (Brodeur, 2003) . The most relevant for neuroblastoma is believed to be ID2, the most-highly expressed in this cancer (Perk et al., 2005) . It is still controversial whether ID2 acts as N-MYC effector, the overexpression of which is found in a significant number of cases and predicts a poor outcome (Vandesompele et al., 2003; Schwab, 2004; Perk et al., 2005) . Here, we report on Id inhibition in human neuroblastoma cells, obtained through a dominant interfering molecule, the HLH domain 13I (Ciarapica et al., 2003) . 13I was isolated from a phage display library of HLH domains harbouring amino acid substitutions in dimerization critical residues. It has the capacity of strongly binding to ID2, whereas non-significantly interacting with bHLH proteins (Ciarapica et al., 2003) . On introduction into neuroblastoma cells, this domain was able to trigger neuronal commitment and differentiation, inhibit proliferation, increase responsiveness to all-trans retinoic acid (RA), inhibit expression of the proangiogenic protein vascular endothelial growth factor (VEGF), and attenuate their tumorigenic properties in vitro. These findings validate 13I as an Id dominant inhibitor and suggest that interfering with Id function may have therapeutic value for neuroblastoma.
Results

13I is an Id dominant-interfering inhibitor
We initially tested whether 13I, which strongly binds in vitro (Ciarapica et al., 2003) , was able to form complexes with ID2 intracellularly, a requirement for its use as inhibitor. To clarify this point, 293T cells were transfected with ID2 and different amounts of FLAG13I expression plasmids, and cell extracts were precipitated with FLAG antibodies. The intracellular binding was confirmed by western blotting analysis of precipitated proteins, Figure 1a , which shows that the FLAG13I chimera bound to ID2 in a dose-dependent manner. This finding indicates that 13I has the capacity to sequester the ID2 HLH domain. We then asked whether 13I affected the ID2 interaction with the retinoblastoma protein RB (Iavarone et al., 1994; Lasorella et al., 2000) . 293T cells were transfected with combinations of ID2, RB and FLAG13I vectors; cell extracts were precipitated with ID2 antibodies and analysed by western blotting. Figure 1b illustrates that the amount of RB coprecipitated with ID2 decreased in parallel with the 13I intracellular amount increase, suggesting that 13I overexpression may relieve ID2 inhibition and promote RB activity. It was important to assess 13I specificity with respect to other Id family members and to E proteins, ubiquitous bHLH transcription factors that represent the Id primary targets. These issues were investigated through pull-down assays with glutathione S-transferase (GST)-linked proteins, on extracts of 293T cells transfected with FLAG13I. The HLH regions of all Ids are highly homologous, hinting that 13I may bind the other Id proteins as well, particularly ID1 and ID3, which are the only ones present in neuroblastoma cells besides ID2 (Lasorella et al., 2000; Jogi et al., 2002) . Figure 1c shows that, as expected, ID1 and ID3 bound to 13I, whereas 13I binding to the HEB E protein dimerization domain was barely detectable, confirming earlier results (Ciarapica et al., 2003) . This suggests that 13I may be capable of targeting all Ids in neuroblastoma cells, without directly affecting the E proteins. To ascertain its efficacy, we tested the ability to relieve Id repression of E proteindependent transcription, through luciferase reporter assays. We transfected a multimerized E-box luciferase reporter into 293T cells, with different combinations of E47, ID2 and FLAG13I vectors. 13I did not impair E47 activity, whereas it relieved ID2 inhibition of E47-mediated transcription in a dose-dependent manner (Figure 2a ). The slight increase in E47-dependent transcription observed in presence of 13I may reflect and cbS-FLAG13I, cell lysates were immunoprecipitated with FLAG antibodies, and analysed by western blotting with FLAG and ID2 antibodies. *Indicates that ID2 and FLAG-13I expression plasmids were used in 1:3 relative amounts. (b) 13I hampers ID2:RB complex formation. pCMV-ID2, pCMV-RB and cbS-FLAG13I transfected 293T cell extracts were immunoprecipitated with ID2 antibodies, and analysed by western blotting with RB, FLAG and ID2 antibodies. *Indicates that ID2, RB and 13I expression plasmids were used in 1:1:3 relative amounts. (c) 13I selectively binds to Ids in vitro. A cbS-FLAG13I transfected 293T cell extract was used for pull down assays with 10 mg GST, GST-ID1, GST-ID3 and GST-HEB dimerization domain (Coomassie staining). The amount of 13I bound to GST control and fusion proteins was detected by western blotting with FLAG antibodies (WB).
inhibition of endogenous Ids. Analogous results were obtained from reporter assays in SH-EP cells (Figure 2b ). These findings suggest that 13I has the properties of a dominant interfering molecule.
13I promotes neuroblastoma cell differentiation
Two cell types, neuroblastic (N) and substrate adherent (S), are present in human neuroblastoma cell lines (Ciccarone et al., 1989) . N-type cells resemble proliferating neuroblasts, and frequently overexpress N-MYC. They display small and loosely adherent cell bodies, have neurite-like processes, and produce neuron-specific proteins. These features are enhanced on RA treatment (Voigt et al., 2000) . S-type cells resemble epithelial cells, and do not overexpress N-MYC. They are large, flattened and strongly adherent, do not display neuronal features, and do not differentiate in response to RA (Wainwright et al., 2001) . They have properties of melanocyte and glial cell lineages, and may represent a multipotent neural crest precursor (Ciccarone et al., 1989) . To test the impact of 13I expression, we took the two cell lines, LA-N-5 and SH-EP, which are N-and S-type, respectively, as models (Wainwright et al., 2001) . N-MYC is amplified and overexpressed in LA-N-5, whereas it is barely detectable in SH-EP cells (Cohen et al., 1988; Vandesompele et al., 2003) .
SH-EP and LA-N-5 cells were infected with FLA-G13I expressing (pBP13I) and control (pBP) pBabePuro retroviruses, and subjected to puromycin selection. Polyclonal populations were collected and examined. 13I and ID1-3 expression was analysed by western blotting (Figures 3a and b , right panels). The ID2 signal was the most intense, ID3 being barely detectable and ID1 intermediate. 13I-infected LA-N-5 and SH-EP cells produced higher amounts of ID1 and ID2 than empty virus-infected controls, implying that 13I upregulates ID1 and ID2. This may either reflect changes in protein stability or be consequent to a negative feedback of ID1 and ID2 on their own expression, as reported for bHLHs like HES1 and MYC (Penn et al., 1990; Hirata et al., 2002) . By affecting Id function, 13I would hamper the feedback control, thus upregulating ID1 and ID2. LA-N-5 cells displayed two-to threefold higher amounts of ID1 and ID2 than SH-EP cells; nevertheless, the 13I signal of infected cells was always stronger than endogenous Ids. 13I expression had quite a different impact on the two cell lines.
Morphological changes were visible in LA-N-5 13I cells, which displayed more marked neuritic processes than control cells ( Figure 3a , left panel). RA treatment enhanced differentiation of both control and LA-N-5 13I cells, which showed a lower nucleus/cytoplasm ratio and increased neuritic extensions. Although 13I reinforced LA-N-5 neuronal characters moderately only, it strikingly affected SH-EP cells ( Figure 3b , left panel). Although control cells were devoid of neuronal features and unaffected by RA, over 50% of 13I-infected SH-EP cells displayed neuronal morphology, with small cell body, large nucleus/cytoplasm ratio, low adherence and multiple neurite-like processes. These features were strongly enhanced on RA treatment. A portion of SH-EP 13I cells still presented the flat shape and substrateadherence of S-type cells ( Figure 3c , left panel). The percentage of flat cells increased on passages in culture (not shown), suggesting that they had a growth advantage. To evaluate whether this correlated to 13I amounts, S were sorted from neuronal-like (N) cells according to greater adhesion to plastic and larger size, and 13I expression analysed by western blotting (Figure 3c , right panel). The flat cells produced much less 13I. Such a correlation suggests that 13I may jointly promote differentiation and restrain growth.
To further support this view, we analysed by immunofluorescence ( Figure 4 ) the expression of neural-cell adhesion molecule (N-CAM) and neurofilament 160 kDa (NF-160), known to be absent in S type and present in N-type cell lines (Ciccarone et al., 1989; Voigt et al., 2000) . NF-160 and N-CAM signals were visible in LA-N-5 and undetectable in SH-EP cells (Figures 4a  and b) . The presence of 13I in LA-N-5 cells was associated with an increased NF-160 expression, N-CAM being unaffected (Figure 4a ). RA treatment significantly enhanced NF-160 in control and 13I-expressing LA-N-5 cells, whereas it strengthened N-CAM only in 13I-expressing cells, although modestly (Figure 4a ). The presence of 13I in SH-EP cells was associated with significant NF-160 and N-CAM signals, undetectable in the control cells (Figure 4b ). RA treatment strongly reinforced NF-160 and N-CAM in 13I expressing, but it was ineffective in control cells (Figure 4b ).
These data suggest that 13I promotes neuronal differentiation, by increasing the neuronal features present in N-type, as well as by committing to a neuronal lineage and triggering differentiation of S-type neuroblastoma cells.
13I reduces SH-EP cell proliferation
Neuroblastoma cell differentiation is accompanied by changes in the cell cycle machinery leading to proliferative arrest (Wainwright et al., 2001) . Therefore, we expected that differentiation induction by 13I was associated with a slower cell growth. To evaluate this aspect, control and 13I-expressing SH-EP cells were plated in equal amounts, grown in presence or absence of RA and counted for up to four days ( Figure 5 ). In both conditions, SH-EP 13I growth was markedly slower than controls. Cell number was reduced to about 40% of control cells after 96 h in the absence of RA. In its presence, SH-EP 13I simply did not proliferate, whereas control cell proliferation was only slowed down. To determine whether the impaired proliferation could be ascribed to alterations in cell cycle regulators, we analysed RB, cyclin D1, and cyclin-dependent kinase (Cdk) inhibitors p21
Cip1 and p27 Kip1 expression by western blot (Figure 6a ). RB is an ID2 target for cell cycle control (Lasorella et al., 2000) . Cyclin D1, p21 Cip1 and p27
Kip1 are modulated by Ids, and are targets of bHLH-mediated control of cell cycle and differentiation . Their expression changes during neuroblastoma differentiation, varying among flat and neuronal-like cells (Wainwright et al., 2001; De los Santos et al., 2007) . Cyclin D1 and p21
Cip1
were present in equal amounts in 13I and control cells (Figure 6a ), and were unaffected by RA treatment (not shown). On the contrary p27 Kip1 , almost undetectable in control cells, was strongly augmented in SH-EP 13I (Figure 6a ). The fraction of underphosphorylated RB versus the global RB amount was also increased in SH-EP 13I cells. A similar accumulation of underphosphorylated RB occurs during RA-induced differentiation of the SH-SY5Y neuroblastoma cell line as well (Liu et al., 2004) . This means that the balance between different, phosphorylated, RB species in SH-EP 13I cells was shifted towards the ones that inhibit cell cycle progression and promote differentiation, in accordance with the observed properties. Underphosphorylated RB accumulation might be due, at least partly, to direct inhibition of cyclin:Cdk complexes caused by the increased p27 (Figure 6b ), suggesting that its upregulation by 13I was consequent to Id inhibition, at least partly. To ascertain whether 13I promoted apoptosis, cells grown for different time periods in presence or absence of RA were stained with propidium iodide and Annexin V. We failed to observe significant differences in apoptotic rate (not shown). This means that differentiation is the major determinant of the proliferative impairment caused by 13I.
13I downregulates VEGF
Inhibitor of DNA binding proteins are important angiogenesis regulators, by promoting proangiogenic gene expression in tumour endothelial cells (Ruzinova and Benezra, 2003) . ID2 upregulates VEGF mRNA and protein in neuroblastoma cells (Lasorella et al., 2005) . To ascertain whether 13I influenced VEGF expression, VEGF mRNA was measured by real time PCR (Figure 7) . The VEGF mRNA amount in SH-EP 13I cells was only 20% of control cells. Transfection of the ID2 vector caused a twofold increase of the VEGF mRNA after 48 h (Figure 7) , indicating that the decreased VEGF expression was caused, in large part, by Id function inhibition.
13I affects SH-EP cell tumorigenic potential
Finally, we tested whether 13I would be effective in restraining the tumorigenic potential of neuroblastoma cells, by in vitro assays for cell migration, invasiveness and anchorage independent-growth. We found that 13I expression entailed a 60-70% decrease in SH-EP cell colony formation in agar ( Figure 8a) ; similar results were obtained with another S-type cell line, SK-N-AS (data not shown). 13I also caused a 45% reduction of SH-EP cells migratory activity (Figure 8b) . A matrigel invasion assay showed that SH-EP cell invasiveness in vitro was reduced by 47% in presence of 13I (Figure 8c) .
Altogether, these findings suggest that 13I may represent a tool for globally interfering with Id function, and that Id inhibition may be effective in counteracting neuroblastoma cell neoplastic properties.
Discussion
Inhibitor of DNA binding proteins have a role in developmental and tumorigenic processes, by forming complexes with a number of transcriptional regulators and inhibiting control of genes involved in growth arrest, differentiation and angiogenesis. As complex formation is mediated by the HLH domain, inhibiting protein-protein interactions involving this domain may effectively hold up Id function. In this paper, we have addressed two questions. Is it feasible to interfere with Id function in mammalian cells by targeting the HLH domain? May such interference have an interest in cancer therapy? The data here reported encourage us to give positive answers.
We have made use of the mutant HLH domain 13I as a dominant interfering molecule. Although employing an inhibitor affecting protein interactions is far less popular than downregulating mRNAs, it may have some advantages. Disease-relevant biological effects depend on complexes to which many proteins participate. Often, a single protein is involved in a variety of interactions, mediated by distinct functional domains, which can have quite different biological consequences. Therefore, it might be therapeutically more sound to inhibit only selected ones. This can best be obtained by molecules acting at the protein level, as RNA interference is unable of discriminating among functional domains of proteins (Tanaka et al., 2007) . Another possibility is that cancer cells may circumvent the inhibition of a single gene of a family, such as Myc or Id, by activating another family member. A reagent targeting protein-protein interactions has a good chance of inhibiting all family members, as their interaction modules usually are almost identical. Protein domain specific reagents may thus have great therapeutic relevance. Such an approach was validated by targeting MYC with the mutant bHLHZip domain Omomyc (Soucek et al., 1998 (Soucek et al., , 2008 .
13I was capable of binding to all Ids present in neuroblastoma cells, a property that may prevent compensating the effects of inhibiting just one Id through the activities of the others. Furthermore, 13I interfered with ID2:RB complex formation, crucial for ID2 ability to promote cell cycle and prevent differentiation (Lasorella et al., 2005) . 13I selectively bound to Ids versus E proteins, and counteracted ID2 negative effect on E47 E protein-dependent gene transcription. This may explain the 13I effect on SH-EP cells, at least partly, as E47 activity prevents cell cycle progression in neuroblastoma cells (Rothschild et al., 2006) . Finally, 13I affected the expression of the Id targets p27 kip1 and VEGF (Lasorella et al., 2005; Chassot et al., 2007) , by turning the first on and the second off. Such a deregulation was reversed by over-producing ID2. Altogether, these findings support our view of 13I as an effective Id inhibitor.
The most striking 13I property was the ability to trigger commitment and differentiation of the S-type neuroblastoma cell line SH-EP. The N-type cell line LA-N-5 was instead only modestly affected. N-type cells express neuron-specific proteins and differentiate in response to RA, whereas S-type cells do not express neuronal proteins and do not differentiate. Id inhibition by 13I caused SH-EP to become very similar to LA-N-5, displaying a neuroblast shape with neuritic extensions and expression of neuron-specific proteins. On RA treatment, SH-EP 13I cells stopped proliferating and strongly enhanced their neuronal features. Therefore, Id function seems to be critical for preventing S-type cells from committing to a neuronal lineage. The weaker sensitivity of LA-N-5 to 13I may have several causes. They produce more ID1 and ID2 than SH-EP cells, and the 13I amount might be insufficient for a full Id inactivation. LA-N-5 also overexpress N-MYC, which might partly bypass the Id activity in differentiation control. The implication of Ids in phenotypic conversion is not unexpected, considering their role in the epithelial to mesenchymal transition and in transforming growth factor b-induced transdifferentiation of renal, mammary, and hepatic cells (Kondo et al., 2004; Wiercinska et al., 2006; Li et al., 2007) , as well as the strong ID2 upregulation during hypoxia induced de-differentiation of neuroblastoma cells (Lofstedt et al., 2004) .
The decreased proliferation and enhanced differentiation of SH-EP 13I cells occurred concomitantly with p27
Kip1 and under-phosphorylated RB accumulation. p27
Kip1 mediates differentiation and proliferative arrest by neurogenic bHLHs (Farah et al., 2000) . Its expression is downregulated by ID2 and ID3, in the latter case through the inhibition of the ETS transcription factor ELK1 (Chassot et al., 2007) . p27 Kip1 accumulation is likely to be because of an increased transcription, as the mRNA amount was augmented in both stably transformed and acutely infected (data not shown) SH-EP cells, suggesting that 13I affects the ID/ELK1 interaction. An increased p27
Kip1 expression may promote accumulation of underphosphorylated, active, RB, by inhibiting Cdks involved in its phosphorylation. Furthermore, 13I might directly enhance RB function, by affecting the RB/ID2 interaction. 13I downregulated VEGF mRNA. Ids and VEGF are connected through a positive feedback loop, with VEGF upregulating Ids, and Ids upregulating VEGF (Sakurai et al., 2004; Lasorella et al., 2005) .
Is all this relevant for neuroblastoma? Low p27 Kip1 levels correlate with poorer outcomes in human cancers, and high p27 Kip1 levels are good prognostic factors in neuroblastoma (Bergmann et al., 2001) . Interestingly, S-and N-cell types usually co-exist within neuroblastoma tumours. S-type cells seem to be more resistant to chemotherapy and unable to differentiate in response to RA, used as neuroblastoma treatment (Reynolds et al., 2003) . Differentiated neuroblastoma cells lose their invasion potential, suggesting that targeting the Id HLH domain similarly to 13I may strengthen RA activity. Increased VEGF production is associated with tumour aggressiveness. The efficacy of Id inhibition in contrasting tumour angiogenesis has been recently shown (Henke et al., 2008) . The relevance of Id inhibition in neuroblastoma is further strengthened by our findings that 13I significantly reduces the tumorigenic properties of SH-EP cells in in vitro assays for anchorage-independent growth, migration and invasiveness.
In all, our results suggest that Id inhibition may have therapeutic potential for treatment of neuroblastoma, and, possibly, other human cancers. A protein domain such as 13I may be efficiently delivered through viral vectors or through carbon nanotubes. Alternatively, it may be used as a lead molecule for the design of therapeutically effective compounds.
Materials and methods
Antibodies and chemicals ID1, ID2, ID3, HEB, cyclin D1, p21
Cip1 and actin rabbit antibodies (sc-488, 489, 490, 357, 717, 397, 10731) were from Santa Cruz, Santa Cruz, CA, USA; N-CAM antibodies (#AB5032) from Millipore Corporate, Billerica, MA, USA; RB, underphosphorylated RB and p27
Kip1 mouse monoclonals (G3-245, G99-549, G173-524) from BD, Franklin Lakes, NJ, USA; FLAG antibodies (M2) affinity gel from Sigma, St Louis, MO, USA; anti NF-160 (MAB-10416) from Immunological Sciences, Roma, Italia; horseradish peroxidase-, rhodamine-and fluorescein-linked secondary antibodies from Chemicon. All chemical from Sigma, except when otherwise indicated.
Expression plasmids 13I was PCR amplified from a phage clone (Ciarapica et al., 2003) and fused to amino acids 634-682 of HEB C-terminal region, known to stabilize HLH domains. The resulting construct was inserted into cbS-FLAG (M Cole, Dartmouth College, Hanover, NH, USA), and sequenced. The FLAG13I fragment was excised and cloned into pBabePuro, thus obtaining pBP13I. pCMV-ID2 was from L Vitelli (ISS, Rome), pCMV-ID1, pCMV-ID3, pGEX2T-ID1 and pGEX2T-ID3 from A Iavarone (Columbia University, New York, NY, USA), pCMV-RB from M Caruso (INMM, Rome) and pcDNA4/HisMaxA-E47 from A Palamarchuk (Columbus, OH, USA). Sapienza, Rome) were cultured in RPMI-1640, and 293T and Phoenix cells in DMEM, supplemented with 10% foetal calf serum (EuroClone, Siziano, Pavia, Italia), at 37 1C in 5% CO 2 . 20 mg pBP and pBP13I DNA were introduced into 5 Â 10 6 Phoenix cells, by calcium phosphate transfection. Retrovirus containing supernatants were collected after 48 h, passed through 0.45 mm Millipore filters, and used to infect subconfluent cultures for 16 h, with 4 mg/ml polybrene. Infected cells were selected by 1 mg/ml puromycin, for 4 weeks. Cells were treated with 10 mM RA for 4 days, by replacing the medium after 48 h. SH-EP and 293T cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Cells
SH
Western blotting
Samples were separated through 10, 12.5 and 15% SDS-PAGE gels, transferred to Hybond ECL membranes (GE HEALTH-CARE BioScience Corporate, Piscataway, NJ, USA), and treated with appropriate antibodies. Staining was performed by SuperSignal Chemiluminescent Substrate (Pierce, Rockford, IL, USA), and densitometric analysis by ImageJ software.
Coimmunoprecipitation cbS-FLAG13I, pCMV-ID2 and pCMV-RB plasmids were transfected into 293T cells. After 2 days, cells were lysed in lysis buffer [10 mM NaCl, 10 mM Tris-HCl (pH 8), 0.3 M sucrose, 3 mM MgCl 2 , 0.5% NP-40], containing protease and phosphatase inhibitors. Protein samples of 1.5 mg were incubated at 4 1C overnight with 1 mg ID2 antibody conjugated to protein A/G Sepharose beads (Pierce), or anti-FLAG affinity gel, and briefly centrifuged. Pellets were washed 5 Â in phosphate buffer saline (PBS) and analysed by western blotting.
Pull-down assay Escherichia coli BL21 cells harbouring plasmids expressing GSTlinked ID1, ID3 and HEB dimerization region (amino acid 580-682) were grown to an OD 600 of 0.6 and treated with 0.1 mM IPTG, 3-5 h at 30 1C. GST-fusion proteins were extracted, and conjugated to glutathione-sepharose 4B beads (GE HEALTH-CARE BioScience Corporate). 293T cells were transfected with cbS-FLAG13I DNA, and lysed in lysis buffer [10 mM NaCl, 10 mM Tris-HCl (pH 8), 0.3 M sucrose, 3 mM MgCl 2 , 0.5% NP-40]. Lysates were cleared by centrifugation, mixed with 10 mg GST control and fusion proteins coupled to glutathionesepharose beads, incubated 2 h at 4 1C and centrifuged. Pellets were washed 5 Â in PBS, and analysed by western blotting.
Luciferase assay Cells, seeded in six-well culture plates, were cotransfected with the E-box-dependent firefly luciferase reporter 4RE-luc (PL Puri, EBRI, Rome), the Renilla luciferase reporter pGL3-Renilla, and combinations of pcDNA4/HisMaxA-E47, pCMV-ID2 and cbS-FLAG13I. Cells were lysed 48 h later, and firefly and Renilla luciferase measured by the dualluciferase reporter assay (Promega, Madison, WI, USA).
Morphology and immunocytochemistry
Cells were visualized with an Eclipse TE200 microscope (Nikon, Sesto Fiorentino, Firenze, Italia) and images acquired through Metamorph software (Crisel, Roma, Italia). Cells grown on glass chamber slides (BD, #354118) were washed 3 Â in PBS, fixed 10 min in 70% ethanol and treated 5 min with 0.2% Triton X-100 in PBS. After 30 min in PBS containing 3% bovine serum albumin, slides were incubated overnight at 4 1C with NF-160 and N-CAM antibodies, washed, incubated 1 h at room temperature with rhodamine-or fluorescein-linked secondary antibodies, washed again, stained 2 min with 200 ng/ml DAPI, and mounted in GelMount (Biomeda, Foster City, CA, USA). Images were acquired by an Eclipse E600 fluorescence microscope, through LUCIA software.
Proliferation
Cells plated in triplicate onto 12 mm diameter multi-well plates (2 Â 10 4 cells/well) were allowed to adhere overnight, harvested at different times, and counted with a hemocytometer. Data reported are the mean of triplicate counts of at least three independent experiments.
RNA analysis
Cells were treated with Trizol (Invitrogen) and RNase-free DNase I (USB, Inc., Cleveland, OH, USA), 30 min at 37 1C. RNA was purified by phenol extraction and inspected by agarose gel electrophoresis. VEGF and p27
Kip1 mRNAs were measured by real time PCR with TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA) through an ABI PRISM 7700: 2 min at 50 1C, 10 min at 95 1C, 40 cycles of 15 s at 95 1C followed by 1 min at 60 1C. At least two independent amplifications were performed for each probe, with triplicate samples. Cycle threshold values were determined by automated analysis.
Invasion and migration assays
Cell ability to penetrate through polycarbonate membranes (8 mm pores, NeuroProbe, Gaithersburg, MD, USA) coated with growth factor reduced (GFR) matrigel for invasion assays, and 5 mg/ml gelatin for migration assays, was measured in Boyden chambers (Toschi et al., 2000) . Cells were loaded in the upper compartment (1 Â 10 5 cells per chamber); NIH-3T3 cell conditioned medium (chemoattractant) or serum-free medium containing 0.1% bovine serum albumin (control), in the lower one. After 20 and 4 h, cells that, respectively, invaded or migrated to the lower compartment were fixed, stained, and eight random fields per slide were counted. Triplicate assays were carried out in two independent experiments. Soft-agar assays A total of 5 Â 10 3 cells were seeded in 3.5 cm plates, in medium containing 0.35% Noble agar. Medium was refreshed every 3 days. On week 4, colonies were counted by microscopic inspection. Colony numbers were normalized by dividing the number of colonies by the number of total units (colonies þ single cells). Triplicate assays were carried out in two independent experiments. Abbreviations bHLH, basic helix-loop-helix; Cdk, cyclin dependent kinase; GST, glutathione S-transferase; N-CAM, neural cell adhesion molecule; NF-160, neurofilament 160 kDa; pBP, pBabePuro; RA, all-trans retinoic acid; VEGF, vascular endothelial growth factor.
